Kissei Pharmaceutical Co., Ltd.
4547.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥88,330,000 | ¥75,579,000 | ¥67,493,000 | ¥65,381,000 |
| % Growth | 16.9% | 12% | 3.2% | – |
| Cost of Goods Sold | ¥44,265,000 | ¥38,238,000 | ¥35,118,000 | ¥34,143,000 |
| Gross Profit | ¥44,065,000 | ¥37,341,000 | ¥32,375,000 | ¥31,238,000 |
| % Margin | 49.9% | 49.4% | 48% | 47.8% |
| R&D Expenses | ¥0 | ¥9,474,000 | ¥10,391,000 | ¥10,363,000 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥38,291,000 | ¥20,790,000 | ¥20,304,000 | ¥19,923,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥3,060,000 | ¥2,808,000 | ¥2,354,000 |
| Operating Expenses | ¥38,291,000 | ¥33,324,000 | ¥33,503,000 | ¥32,640,000 |
| Operating Income | ¥5,774,000 | ¥4,017,000 | -¥1,129,000 | -¥1,402,000 |
| % Margin | 6.5% | 5.3% | -1.7% | -2.1% |
| Other Income/Exp. Net | ¥9,836,000 | ¥10,432,000 | ¥14,809,000 | ¥17,909,000 |
| Pre-Tax Income | ¥15,610,000 | ¥14,449,000 | ¥13,680,000 | ¥16,507,000 |
| Tax Expense | ¥3,634,000 | ¥3,159,000 | ¥3,046,000 | ¥3,475,000 |
| Net Income | ¥11,961,000 | ¥11,160,000 | ¥10,528,000 | ¥12,921,000 |
| % Margin | 13.5% | 14.8% | 15.6% | 19.8% |
| EPS | 274.2 | 246.58 | 228.3 | 280.19 |
| % Growth | 11.2% | 8% | -18.5% | – |
| EPS Diluted | 274.2 | 246.58 | 228.3 | 280.19 |
| Weighted Avg Shares Out | 43,622 | 45,258 | 46,115 | 46,115 |
| Weighted Avg Shares Out Dil | 43,622 | 45,258 | 46,115 | 46,115 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥57,000 | ¥21,000 | ¥23,000 | ¥42,000 |
| Interest Expense | ¥21,000 | ¥18,000 | ¥20,000 | ¥23,000 |
| Depreciation & Amortization | ¥4,615,000 | ¥4,254,000 | ¥4,109,000 | ¥3,730,000 |
| EBITDA | ¥20,250,000 | ¥18,720,000 | ¥17,808,000 | ¥20,261,000 |
| % Margin | 22.9% | 24.8% | 26.4% | 31% |